Background and Purpose-Microhemorrhages on gradient-echo T2*-weighted MRI sequences are often found in patients with cerebrovascular disease and are related to intracerebral hemorrhage. Because statin therapy is associated with increased risk of intracerebral hemorrhage, we investigated whether statin use was also associated with microhemorrhages in patients with acute ischemic stroke or transient ischemic attack. Methods-We performed a retrospective analysis on prospectively collected data from a stroke registry containing patients with acute ischemic stroke or transient ischemic attack. The primary and secondary outcome variables were the prevalence and degree of microhemorrhages as detected on gradient-echo MRI sequences and categorized as mild (1-2), moderate (3-10), or severe (Ͼ10). The location of the microhemorrhages was noted and rated by 2 neuroradiologists. Previous use of statins and other covariates were assessed as potential predictors. Results-Three hundred forty-nine patients were admitted from June 2008 to July 2009, and 300 of which were analyzed.
F oci of signal loss on gradient-echo (GRE) T2*-weighted MRI are histopathologically correlated to microhemorrhages and are related to a microangiopathy. 1 These lesions have been correlated with both ischemic and hemorrhagic stroke, as well as with the risk of recurrent stroke. [2] [3] [4] [5] [6] [7] [8] The prevalence of microhemorrhages in patients with ischemic stroke is estimated to be 23% to 40% and is associated with future intracerebral hemorrhage (ICH). 3-7,9 -13 Risk factors associated with microhemorrhages include hypertension, microvascular white matter disease (WMD), ICH, ischemic stroke, antiplatelet use, low total serum cholesterol, reduced serum low-density lipoprotein cholesterol (LDL-C), and increased serum high-density lipoprotein cholesterol levels. 6,14 -19 The location of microhemorrhages correlates with the underlying disease with the cortical-subcortical location, suggesting cerebral amyloid angiopathy or Alzheimer disease 4, 18 and deeper lesions hypertension. 4, 15, 18 Statin therapy lowers LDL-C, total cholesterol, and C-reactive protein, and it increases high-density lipoprotein cholesterol levels. High-dose atorvastatin increased the risk of ICH in patients with cerebrovascular disease, 20, 21 particularly among patients with previous ICH. 22 A potential association between statin use and the prevalence or degree of microhemorrhages in patients without ICH would imply the effect of statins is part of a continuum starting with an asymptomatic state and leading to overt ICH. We tested the hypothesis that previous statin use is associated with an increased prevalence or degree of microhemorrhages in patients with acute ischemic stroke or TIA.
Materials and Methods
Data of patients with acute ischemic stroke or TIA admitted to our institution from June 2008 to July 2009 were prospectively collected in a stroke registry. We retrospectively identified patients older than age 55 years admitted for ischemic stroke or TIA and had an acute MRI performed at our institution. The previous use of statins, age, gender, race, diffusion-weighted image abnormality, and medical history were recorded and correlated with GRE lesions and WMD identified.
Clinical variables analyzed were hypertension, diabetes, hyperlipidemia, previous stroke, peripheral vascular disease, history of ischemic heart disease, congestive heart failure, valve disease, prosthetic heart valve, atrial fibrillation or flutter, current smoker, alcohol use, drug abuse, and previous use of aspirin, warfarin, heparin, aspirin and extended-release dipyridamole, or ticlopidine/ clopidogrel. No data were available regarding duration of statin use, type, or dose. Degree of blood pressure control or statin-related adverse events were not recorded in the registry.
MRI Analysis of GRE Lesions, Diffusion-Weighted Imaging Lesions, and WMD
MRI were performed on a Siemens 3-T Trio, 1.5-T Espree, or 1.5-T Avanto scanners. The protocol consisted of an axial T2-weighted spin-echo (repetition time, 4000 ms; echo time, 80 -112 ms; flip angle, 180 degrees; slice thickness, 5 mm; gap width, 2 mm), axial T2*-weighted GRE sequences (repetition time, 500 -600 ms; echo time, 20 ms; flip angle, 20 degrees; slice thickness, 5 mm, gap width, 2 mm), axial diffusion (repetition time, 2900 ms; echo time, 79 ms; slice thickness, 5 mm, gap width, 1 mm), and axial FLAIR (repetition time, 9000 ms; echo time, 109 ms; flip angle, 180 degrees; slice thickness, 5 mm; gap width, 2 mm).
GRE lesions were quantified by 2 neuroradiologists (B.P., W.S.) as determined by consensus utilizing the methods described by the Brain Observer MicroBleed Scale. 23 Microhemorrhages were defined as small, homogenous, round foci of low signal intensity on T2*-weighted images Ͻ10 mm in diameter. Lesions within infarcts were not counted. Common mimics including flow voids in small cortical vessels, hypointensity at sites of deep perforators from the proximal middle cerebral artery, and symmetrical hypointensities in the globus pallidus were excluded. 24 Lesions that were classified "certain" as outlined by the Brain Observer MicroBleed Scale were considered for analysis. By utilizing the Brain Observer MicroBleed Scale, 23 the location could be classified as "lobar" (cortical/subcortical white matter), "deep" (basal ganglia, internal/external capsule, thalamus, brain stem, and cerebellum), or mixed "lobar and deep."
The primary outcome variable of interest was the prevalence of microhemorrhages. A secondary outcome variable was the degree of microhemorrhages, all determined by consensus. MRI FLAIR imaging was reviewed and the semiquantitative scale was applied (0, absent; 1, punctuate; 2, early confluent; 3, confluent) using the methodology described by Fazekas et al. 25 
Statistical Methods
For univariate analysis, comparisons between potential predictors and the presence of microhemorrhages were performed using t test (continuous variables) and 2 test (categorical variables). A multivariate logistic regression analysis was performed for variables with an association at the 0.10 level of significance and the previous use of statins, adjusting for demographic variables, gender, race, and magnet strength.
The degree of microhemorrhages was classified as an ordinal variable indicating mild (1-2), moderate (3) (4) (5) (6) (7) (8) (9) (10) , and severe (Ͼ10), as described by Lee et al. 14 The same predictors that were included in the multivariate analysis of prevalence were also included in the analysis for the degree of microhemorrhages as determined by 1-way ANOVA (continuous predictors), as well as the test for independence in contingence table (categorical predictors) in univariate analysis. A proportional odds model was fitted for those variables with an association at the 0.10 level of significance in the univariate analysis and the previous use of statins, adjusting for demographic variables, gender, race, and the magnet strength. A "lower" degree of microhemorrhages as compared to a "higher" degree of microhemorrhages was defined by either mild disease vs moderate/severe disease or mild/moderate disease vs severe disease.
For the categorization of the WMD, the Fazekas scale 25 was applied to FLAIR imaging with ratings of both 0 or 1 (normal) compared to the rating of 2 or 3 (WMD). 25 Analyses were performed using SAS 9.2. The study was approved by the Institutional Review Board of the University of Iowa.
Results
Forty-nine of 349 patients with acute ischemic stroke or TIA were excluded because of intraventricular hemorrhage (nϭ15), no GRE sequence (nϭ14), brain tumor (nϭ8), no MRI at admission or MRI performed at another institution (nϭ3), no FLAIR performed (nϭ1), previous craniectomy (nϭ1), missing record (nϭ1), poor study quality (nϭ1), suspected abscess (nϭ1), previous head and neck radiation (nϭ1), concurrent ICH (nϭ2), or traumatic brain injury (nϭ1).
The ages of the remaining 300 patients ranged from 55 to 98 (mean, 71Ϯ10.3) years and 58.7% were men. Two hundred fifty patients (83.3%) were studied with 1.5-T MR units and the remainder was studied with 3.0-T MR units. Microhemorrhages were detected in 70 subjects (23%) with a prevalence of 24% in patients scanned with 1.5-T MR units and 18% scanned with 3.0-T MR units (Pϭ0.33). Of the 256 subjects with positive diffusion-weighted imaging, 64 (25%) had microhemorrhages and 6 of 44 (13.6%) with negative diffusion-weighted imaging had microhemorrhages (Pϭ0.10). Among subjects with microhemorrhages, 35 had only "lobar" lesions, 16 had only "deep" lesions, and 19 had both. Of the 40 subjects with 1 microhemorrhage, 26 had a lobar lesion and 14 had a deep lesion.
Demographic and clinical data are presented in Table 1 . On univariate analysis, previous use of statins was not associated with the prevalence of microhemorrhages (Pϭ0.63). Microhemorrhages were significantly associated with age (Pϭ0.01), ischemic heart disease (Pϭ0.02), and WMD (Pϭ0.04), and were inversely associated with total cholesterol (PϽ0.01) and LDL-C (Pϭ0.03).
On multivariate analysis, the previous use of statins was also not significantly associated with microhemorrhages (OR, 0.73; 95% CI, 0.36 -1.51; Pϭ0.40). Only ischemic heart disease was an independent predictor of microhemorrhages (OR, 2.50; 95% CI, 1.15-5.42; Pϭ0.02; Table 2 ).
Univariate analysis showed no association between previous use of statins and the degree of microhemorrhages (Pϭ0.58) but showed a significant association with WMD (PϽ0.01), previous stroke (PϽ0.01), and previous use of warfarin (Pϭ0.02; Table 3 ). The multivariate analysis showed that WMD, previous stroke, and previous warfarin use all reduced the likelihood of a lower degree of microhemorrhages (Table 4 ). The multivariate analysis for the previous use of statins showed no significant association (OR, 2.31; 95% CI, 0.61-8.75; Pϭ0.22).
Discussion
The overall prevalence of microhemorrhages in our patients (23%) is in agreement with previous studies. 4, 9, 10 Although not statistically significant, the prevalence of microhemorrhages was greater among those with an abnormal diffusionweighted imaging scan compared to those without. Previous studies comparing ischemic stroke with TIA and populationbased studies report similar findings. 4, 7, 10, 18, 26 The primary purpose of this study was to evaluate whether statin therapy influenced the presence and degree of microhemorrhages. Despite the potential association of statin therapy and ICH, 20, 21 neither univariate nor multivariate analysis demonstrated any association of previous statin use and microhemorrhages. Another recent study also showed no association between statin therapy and microhemorrhages. 27 Because statins are prescribed for the secondary prevention of ischemic cerebrovascular disease, 20,28 -30 an entity associated with microhemorrhages, 2,4,7,8,10,11,16 -18 the independent association of statin use with microhemorrhages would be of concern. Our results suggest that the potential mechanism of statin-associated ICH is not mediated by an increase in microhemorrhages.
The mechanism of increased risk of ICH with statin use is unknown. In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, LDL-C levels were not related to ICH, 31 whereas hemorrhagic stroke as the entry event or increasing age was significantly associated with ICH. 22 This suggests that statin-associated ICH may be independent of LDL-C levels. On univariate analysis, we found an inverse association of LDL-C levels and microhemorrhages. Statins also affect the coagulation cascade and fibrinolytic system, which could also increase ICH risk. 32, 33 Microhemorrhage prevalence in ischemic cerebrovascular disease was reported to be highest (62.2%) in the lacunar stroke subtype. 7 Although stroke subtype was not investigated in the present study, previous ischemic heart disease was significantly associated with microhemorrhages, suggesting the association may not be limited to small vessel disease. 34, 35 Previous warfarin use, history of stroke, and WMD were all independently associated with the degree of microhemorrhages, as in previous studies. 2-8,10,16 -18,36 -38 An increased prevalence and number of cerebral microhemorrhages have been associated with warfarin-related ICH. 36 Prospective data implicating a specific warfarin-related influence on microhemorrhage lesion prevalence or subsequent evolution into ICH are limited. 38 In our study, antiplatelet therapy was not found to be associated with microhemorrhages; however, other studies report an association, 6, 12, 19, 38 although inconsistent. 7, 38 Also, the association may only involve lobar 19 or mixed cortical-subcortical 6 lesions.
Our study has limitations. Because of the design, this retrospective study measured microhemorrhages as an outcome variable rather than as a marker influencing a prospective disease end point. Some of the explanations for the difference in the variables associated with microhemorrhages may be attributable to confounding, a lack of causality, or lack of a dose-effect relationship. Hypertension may not have been associated with microhemorrhages because of the high prevalence of hypertension in both groups. Our database is dependent on chart extraction and personally reported medical history. Information regarding the type of statin used, dose, duration, and previous blood pressure control was unavailable, so subgroup analyses regarding these issues could not be performed. A final limitation is the use of 1.5-T and 3.0-T MR scanners. One study suggested that 3.0-T MRI is more sensitive in detecting microhemorrhages; 39 however, we found no significant difference between the detection or degree of microhemorrhages in individuals scanned with 1.5-T compared to 3.0-T scanners.
The strengths of this study include a careful review of MR scans by 2 trained neuroradiologists. Previously validated methods were used to identify and classify the degree of microhemorrhages and WMD. 14, 23, 25 
Conclusion
The use of statin therapy before index stroke or TIA does not influence the prevalence or degree of microhemorrhages. Our results suggest that the mechanism of statin-related ICH is not mediated by the presence of microhemorrhages.
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